Christian C. Dibble
Identified TBC1D7 as the third subunit of the TSC complex that controls mTORC1, as a Manning-lab graduate student. His lab at Beth Israel Deaconess studies how PI3K signalling and nutrient supply are integrated to control mTORC1 and cell metabolism
Assistant Professor of Pathology, Beth Israel Deaconess Medical Center & Harvard Medical School · PhD, Brendan Manning lab, Harvard T.H. Chan School of Public Health · postdoc, Beth Israel Deaconess Medical Center (Lewis Cantley lab)
Dibble Lab, BIDMC & Harvard (Boston, Massachusetts, USA) ↗ Lab lineagetrained under Brendan D. Manning → Bluesky@dibblelab.bsky.social ↗ ORCID0000-0002-1122-9017 ↗
Portrait: Dibble Lab, Beth Israel Deaconess Medical Center
Christian Dibble did his PhD in Brendan Manning's lab at Harvard, where he worked out how the TSC1/TSC2 complex integrates growth-factor and nutrient signals to control mTORC1.
In 2012 he identified TBC1D7 as a third, stably associated subunit of the TSC1-TSC2 complex, completing its core composition, and went on to review how PI3K signalling and nutrient cues are integrated by mTORC1 to coordinate a cell's biosynthetic output with its nutrient supply. He now runs his own lab at Beth Israel Deaconess Medical Center and Harvard Medical School.
The timeline below follows Dibble's contributions gathered in this Atlas.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2012 | M | TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1 DIB2012 Identifies TBC1D7 as a third, stably associated subunit of the TSC1-TSC2 complex upstream of mTORC1. |
| 2013 | R | Signal integration by mTORC1 coordinates nutrient input with biosynthetic output DIB2013 Reviews how mTORC1 performs signal integration, coordinating nutrient input with a cell's biosynthetic output. |
| 2014 | M | Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome MEN2014 Spatial control of the TSC complex integrates insulin and nutrient inputs at the lysosome. |
| 2015 | R | Regulation of mTORC1 by PI3K signaling DIB2015 Reviews how PI3K signalling regulates mTORC1. |
Co-authors in the Atlas 10
People with a profile here who share at least one study with Christian C. Dibble.
ShowHide
- Brendan D. Manning 3 shared studies Was among the groups that in 2002 identified TSC2 as a direct target of Akt (MAN2002), linking insulin and PI3K signalling to mTORC1, and later found TBC1D7 as the third subunit of the TSC complex. His lab has shown how mTORC1 turns growth signals into the synthesis of lipids and nucleotides
- Lewis C. Cantley 2 shared studies Co-discovered PI3K, the pathway that feeds into mTOR from growth factors
- Alexander J. Valvezan Showed as a Manning-lab postdoc that mTORC1 matches nucleotide production to demand, creating a weak point that can be targeted in tumours with TSC loss. His Rutgers lab found that mTORC1 activity rises and falls through the cell cycle and helps drive entry into mitosis
- David J. Kwiatkowski Geneticist and physician who studies tuberous sclerosis complex (TSC) and the TSC1/TSC2 genes that restrain mTORC1.
- George Talbott Research assistant in Brendan Manning's mTOR lab at Harvard in 2013 and 2014, who contributed to studies on where the TSC complex sits in the cell and how metformin reaches mTORC1
- Gerta Hoxhaj Studies how growth signalling through PI3K, AKT and mTOR rewires cell metabolism; as a Manning-lab postdoc she co-authored work on how metformin inhibits mTORC1 in the liver
- John M. Asara Mass-spectrometry specialist whose core facility supplied metabolomics and proteomics for several mTOR studies, including measurements of purine, pyrimidine and SAM metabolism downstream of mTORC1.
- Leon O Murphy Cell biologist who led autophagy and mTOR drug discovery at Novartis in Cambridge, Massachusetts, and is now Chief Scientific Officer of Casma Therapeutics, a company that develops drugs acting on the autophagy-lysosome system
- Peter M Finan Biochemist and drug-discovery leader who started the PI 3-kinase drug discovery program at Novartis and ran its Developmental and Molecular Pathways group in Cambridge, Massachusetts, before moving into life-science venture investing
- Sue Menon Showed insulin controls mTORC1 by moving the TSC complex on and off the lysosome
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.